441 related articles for article (PubMed ID: 9118813)
1. Drug treatment of depression in the 1990s. An overview of achievements and future possibilities.
Möller HJ; Volz HP
Drugs; 1996 Nov; 52(5):625-38. PubMed ID: 9118813
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of the new antidepressants.
Nelson JC
J Clin Psychiatry; 1997; 58 Suppl 6():26-31. PubMed ID: 9227670
[TBL] [Abstract][Full Text] [Related]
3. [Applications and safety of modern antidepressants in patients with liver diseases].
Dubarek W; Kucia K
Wiad Lek; 2007; 60(1-2):28-33. PubMed ID: 17607965
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants.
Augustin BG; Cold JA; Jann MW
Pharmacotherapy; 1997; 17(3):511-30. PubMed ID: 9165554
[TBL] [Abstract][Full Text] [Related]
5. Antidepressants.
Frazer A
J Clin Psychiatry; 1997; 58 Suppl 6():9-25. PubMed ID: 9227669
[No Abstract] [Full Text] [Related]
6. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Horst WD; Preskorn SH
J Affect Disord; 1998 Dec; 51(3):237-54. PubMed ID: 10333980
[TBL] [Abstract][Full Text] [Related]
7. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression.
Kent JM
Lancet; 2000 Mar; 355(9207):911-8. PubMed ID: 10752718
[TBL] [Abstract][Full Text] [Related]
8. New antidepressant drugs and the treatment of depression in the medically ill patient.
Stoudemire A
Psychiatr Clin North Am; 1996 Sep; 19(3):495-514. PubMed ID: 8856814
[TBL] [Abstract][Full Text] [Related]
9. Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Stahl SM
J Clin Psychiatry; 1998; 59 Suppl 18():23-9. PubMed ID: 9840195
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant options: venlafaxine in perspective.
Thase ME
J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):10S-18S; discussion 18S-20S. PubMed ID: 8784644
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions of antidepressants.
Richelson E
J Clin Psychiatry; 1998; 59 Suppl 10():22-6. PubMed ID: 9720479
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine: a 2003 update.
Gutierrez MA; Stimmel GL; Aiso JY
Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of venlafaxine in comparison with other antidepressants.
Lecrubier Y
Int Clin Psychopharmacol; 1995 Mar; 10 Suppl 2():29-35. PubMed ID: 7622815
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary trends in the pharmacotherapeutic management of depression.
Nemeroff CB
J Clin Psychiatry; 1994 Dec; 55 Suppl():3-15; discussion 16-7. PubMed ID: 7814356
[TBL] [Abstract][Full Text] [Related]
15. Practical considerations for the treatment of depression in elderly and very elderly long-term care patients.
Salzman C
J Clin Psychiatry; 1999; 60 Suppl 20():30-3. PubMed ID: 10513856
[TBL] [Abstract][Full Text] [Related]
16. Venlafaxine: a novel antidepressant that has a dual mechanism of action.
Andrews JM; Ninan PT; Nemeroff CB
Depression; 1996; 4(2):48-56. PubMed ID: 9160640
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide.
Goldberg RJ
Drugs Aging; 1997 Aug; 11(2):119-31. PubMed ID: 9259175
[TBL] [Abstract][Full Text] [Related]
18. Three new antidepressants.
Drug Ther Bull; 1996 Sep; 34(9):65-8. PubMed ID: 8885497
[No Abstract] [Full Text] [Related]
19. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
[TBL] [Abstract][Full Text] [Related]
20. Antidepressant effectiveness in severe depression and melancholia.
Schatzberg AF
J Clin Psychiatry; 1999; 60 Suppl 4():14-21; discussion 22. PubMed ID: 10086479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
